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A novel bluetongue virus (BTV) termed Toggenburg or-
bivirus (TOV) was detected in goats from Switzerland by us-
ing real-time reverse transcription–PCR. cDNA correspond-
ing to the complete sequence of 7 of 10 double-stranded 
RNA segments of the viral genome was ampliﬁ  ed by PCR 
and cloned into a plasmid vector. Five clones for each ge-
nome segment were sequenced to determine a consensus 
sequence. BLAST analysis and dendrogram construction 
showed that TOV is closely related to BTV, although some 
genome segments are distinct from the 24 known BTV se-
rotypes. Maximal sequence identity to any BTV ranged from 
63% (segment 2) to 79% (segments 7 and 10). Because 
the gene encoding outer capsid protein 2 (VP2), which de-
termines the serotype of BTV, is placed within the BTV se-
rogroup, we propose that TOV represents an unknown 25th 
serotype of BTV.
B
luetongue is a vectorborne disease affecting all ru-
minant species but causing clinical disease mostly in 
sheep; cattle and goats are usually considered asymptom-
atic reservoir hosts (1). The disease occurs worldwide and 
is caused by bluetongue virus (BTV), which belongs to 
the genus Orbivirus within the family Reoviridae. Other 
species of the orbiviruses are African horse sickness virus, 
epizootic hemorrhagic disease virus (EHDV), and some 
lesser-known viruses such as Peruvian horse sickness vi-
rus, Chuzan virus, Saint Croix River virus, and Yunnan 
orbivirus (2). The virus has a segmented double-stranded 
RNA genome consisting of 10 segments that code for 11 
viral proteins. BTV is transmitted between its ruminant 
host mainly by blood-feeding midges of the Culicoides 
spp. Twenty-four serotypes of BTV can be distinguished 
on the basis of the antigenic proﬁ  le of its major outer capsid 
protein VP2 (3).
In Europe, several serotypes of BTV were detected 
sporadically in the 1990s (4). From 1998 through 2006, a 
total of 5 serotypes (1, 2, 4, 9, and 16) became established 
in southern Europe (5), but they were kept conﬁ  ned to this 
area, most likely because their main insect vector, C. imi-
cola, has never been detected north of the Alps in Europe 
(6). A BTV-monitoring program in cattle herds has been in 
effect in Switzerland since 2003 in Ticino Canton, south of 
the Alps (7–9). However, no BTV has been detected until 
now in this region of the country. Furthermore, northern 
Europe had never been affected by bluetongue before 2006, 
although BTV can also be transmitted by other Culicoides 
species, such as C. obsoletus and C. pulicaris (6), which are 
native to this area. 
In 2006, BTV serotype 8 (BTV-8) of likely African 
origin was introduced into Belgium by an as yet unknown 
mechanism (8). This virus spread throughout many north-
ern European countries. By mid-2008, BTV-8 had caused 
numerous clinical bluetongue cases in sheep and cattle in 
the Netherlands, Belgium, Germany, Luxembourg, France, 
Denmark, Czech Republic, United Kingdom, Italy, Spain, 
and Switzerland (5).
The ﬁ  rst clinical case of bluetongue caused by BTV-8 
in Switzerland was detected in October 2007 on a dairy 
cattle farm (10). Because Switzerland was already includ-
ed in a surveillance zone and, after detection of the ﬁ  rst 
BTV-8 infection, a protection zone, all animals were tested 
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serologically and virologically before trade. Four addition-
al cases of BTV-8 infection were detected from October 
through November 2007 (10,11).
Early in 2008, several BTV-positive, clinically healthy 
animals were detected in a goat ﬂ  ock in northeastern Swit-
zerland (V. Chaignat et al., unpub. data) by BTV-speciﬁ  c 
antibody ELISAs and viral RNA detection, by using a 
BTV-speciﬁ   c real-time reverse transcription–PCR (rRT-
PCR) (10,12). However, levels of antibody and viral RNA 
were unexpectedly low. Furthermore, presence of BTV 
RNA could not be conﬁ  rmed by use of other BTV-speciﬁ  c 
rRT-PCR protocols (13,14), and ampliﬁ  cation curves ob-
tained in the screening rRT-PCR suggested that the target 
sequence on RNA segment 10 of this virus might be dif-
ferent from all known BTV strains (data not shown). For 
this reason, we determined the nucleotide sequence of the 
rRT-PCR ampliﬁ  cation product.
Experimental infection of goats and sheep by subcuta-
neous and intravenous injection of blood from virus-posi-
tive animals from the herd in which the infection was ﬁ  rst 
discovered demonstrated that the virus is transmissible to 
and replicates in goats, albeit without causing bluetongue-
speciﬁ  c clinical symptoms. In contrast, the virus could only 
be sporadically detected in inoculated sheep (V. Chaig-
nat et al., unpub. data). On the basis of the sequence of 
the rRT-PCR product, this newly detected virus, termed 
Toggenburg orbivirus (TOV), could represent an unknown 
orbivirus of low pathogenicity, or a new serotype of BTV. 
Thus, we performed a detailed genetic characterization of 
the TOV genome.
The complete coding sequence for the 7 RNA segments 
(2, 5, 6, 7, 8, 9, and 10) was determined. Segment 2 was 
chosen because it encodes the viral structural protein VP2 
that contains the serotype-speciﬁ  c determinants, whereas 
the genome segments 5 through 10 are short enough to 
enable sequencing of the cloned cDNA without the need 
for internal sequencing primers. We present evidence that 
TOV is genetically related to BTV but cannot be assigned 
to any of the 24 known serotypes; instead, it likely repre-
sents a 25th BTV serotype.
Materials and Methods
Source of Viral RNA and Extraction of RNA
BTV-like orbivirus RNA and antibodies were detected 
in several adult and newborn goats in a herd in the north-
eastern part of Switzerland (St. Gallen Canton) (V. Chaig-
nat et al., unpub. data). We used erythrocytes from blood 
collected into tubes containing EDTA from 1 adult and 1 
newborn goat, which had cycle threshold (CT) values of 
22 and 32, respectively, in the rRT-PCR (10). Total RNA 
was extracted from 250 μL of erythrocyte suspension by 
using Trizol (Invitrogen, Basel, Switzerland) according to 
the manufacturer’s instructions. Precipitated puriﬁ  ed RNA 
was dissolved in 20 μL of RNase-free water.
RT-PCR for Full-Length cDNA Ampliﬁ  cation, 
Cloning, and Sequencing
Primers corresponding to inter-BTV serotype-con-
served 5′ and 3′ terminal sequences were designed for each 
of the viral RNA segments to be analyzed (Table 1). Before 
RT-PCR, 8 μL of extracted viral RNA was mixed with 50 
pM of 2 RNA segment-speciﬁ  c forward and reverse prim-
ers and heat-denatured for 5 min at 95°C. Reverse transcrip-
tion of both RNA strands into double-stranded cDNA was 
performed by using SuperScript III reverse transcriptase 
(Invitrogen) in a ﬁ  nal volume of 25 μL. A total of 8 μL of 
cDNA was then added to a PCR mixture containing Plati-
num Taq High Fidelity Polymerase (Invitrogen) and am-
pliﬁ  ed by 40 cycles at 95°C for 30 s, 50°C for 1 min, and 
72°C for 1 min (for segments 5–10) or 72°C for 8 min (for 
segment 2).
PCR-ampliﬁ  ed cDNA of the expected length was puri-
ﬁ  ed by agarose gel electrophoresis and ligated into plasmid 
vector pCR4-TOPO (Invitrogen). Clones of transformed 
Escherichia coli harboring the TOV insert-containing vec-
tor were identiﬁ  ed by PCR preps using insert-spanning M13 
primers. Miniprep DNA of >5 cDNA clones from each viral 
genome segment was sequenced by cycle sequencing using 
IRD800 and IRD700 infrared dye–labeled M13 (Euroﬁ  ns 
MWG Operon, Ebersberg, Germany) and TOV segment 
2–speciﬁ   c internal primers. Sequencing reactions were 
subjected to electrophoresis in a 4300L DNA sequencer 
(LI-COR, Lincoln, NE, USA) and analyzed by using e-Seq 
V3.0 and AlignIR V2.0 software (LI-COR). The coding re-
gion of each TOV genome segment analyzed in this study 
was compared with published orbivirus sequences by using 
online BLAST analysis (http://blast.ncbi.nlm.nih.gov/blast.
cgi). For phylogenetic analysis, TOV-speciﬁ  c sequences 
were aligned to a selection of available corresponding se-
quences from GenBank that represented all orbivirus spe-
cies by using MEGA version 4.0 software (15) with default 
parameters. The open reading frame (ORF) sequences of 
the 7 analyzed genome segments of TOV were submitted to 
GenBank under accession nos. EU839840 (S2), EU839841 
(S5), EU839842 (S6), EU839843 (S7), EU839844 (S8), 
EU839845 (S9), and EU839846 (S10).
Results
TOV was initially detected by using an RNA segment 
10–speciﬁ  c rRT-PCR (10). Nucleotide sequencing of this 
rRT-PCR product indicated that TOV is an orbivirus close-
ly related to, but not identical with, any known BTV sero-
type. The analyzed sequence showed a 1-base mismatch in 
the probe region of the rRT-PCR target sequence (Figure 
1, panel A), which could explain the unusual ampliﬁ  cation 
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curves (low delta Rn value, the magnitude of the signal gen-
erated by the given set of PCR conditions). Various addi-
tional rRT-PCR protocols all yielded negative results (data 
not shown). When the primer and probe sequences of these 
published rRT-PCR protocols for segment 1 (13,14) or seg-
ment 5 (14), respectively, were aligned to the correspond-
ing TOV sequences determined in this study, numerous 
mismatches were found (Figure 1). These mismatches were 
the likely reason for the failure of these assays to detect 
TOV. Because sequence ampliﬁ  ed by the rRT-PCR (Figure 
1, panel A) was most closely related to several BTV-4 and 
BTV-10 serotypes, RNA segment–speciﬁ  c primers bind-
ing to the conserved 3′ and 5′ untranslated regions were 
designed on the basis of these serotypes whenever no con-
sensus sequence matching with all published sequences 
(representing all 24 serotypes) could be found, i.e., for seg-
ments 2 and 6.
Although the amount of viral RNA in blood from in-
fected but clinically healthy goats was low (CT values >30 
in the rRT-PCR) we could amplify the full-length cDNA 
sequence for all 7 RNA segments analyzed, including the 
2.9-kb fragment of segment 2. PCR products all showed the 
expected length as predicted from the corresponding BTV 
genome segment. After cloning into the pCR4-TOPO vec-
tor, both DNA strands of 5 clones were sequenced for each 
genome segment. A consensus sequence could be unam-
biguously determined because the number of point muta-
tions in the clones was low, and never more than 1 of the 
5 clones showed a difference from the consensus sequence 
(data not shown).
BLAST analysis of the 7 TOV genome segments 
showed in all cases the highest sequence similarity to BTV, 
although the search algorithm had to be changed from me-
gablast (highly similar sequences) to blastn (somewhat 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 12, December 2008  1857 
Table 1. Terminal primers used to amplify complete Toggenburg orbivirus RNA segments 
Name* Sequence  (5ƍ ĺ3ƍ) 
RNA segment  Forward primer 
2 BTV4&10_S2_-21_F GGGTTAAAAGAGTGTTCYAC 
5 BTV_S5_F  GTTAAAAAAGTTCTCTAGTTGGCA 
6 BTV4&10&11_S6_-30_F  GTTAAAAAGTRTTCTCCTACTC 
7 BTV_S7_-17_F  GTTAAAAATCTATAGAGATGGAC 
8 BTV_S8_-19_F  GTTAAAAAAWCCTTGAGTCATG 
9 BTV_S9_-15_F  GTTAAAAAATCGCATATGTCAG 
10 BTV_S10_F  GTTAAAAAGTGTCGCTGCCAT 
 Reverse  primer 
2 BTV4&20_S2_R  GTAAGTGTAAGAAGGCCACAG 
5 BTV_S5_R  GTAAGTTGAAAAGTTCTAGTAGAG 
6 BTV4&10_S6_1618_R GTAAGTGTAATCTTCTCCCTC 
7 BTV_S7_1142_R  GTAAGTGTAATCTAAGAGACGT 
8 BTV_S8_1106_R GTAAGTGTAAAATCCCCCCC 
9 BTV_S9_1038_R  GTAAGTRTGAAATCGCCCTAC 
10 BTV_S10_R  ACCTYGGGGCGCCACTC 
*BTV, bluetongue virus. 
Figure 1. Nucleotide sequence alignment of 
target regions of published bluetongue virus 
(BTV) real-time reverse transcription–PCR 
primers and probes (in boldface), which were 
used for detection of Toggenburg orbivirus (TOV). 
A) Segment 10 (10); B) segment 1, eastern 
serotype speciﬁ  c (13); C) segment 1, western 
serotype speciﬁ  c (13); D) segment 1 (14); E), 
segment 5 (14). Shaded areas indicate primer 
and probe sequences (in sense orientation), 
colons indicate sequence identity, arrows 
indicate orientations of probes and primers, and 
asterisks indicate mismatches between primers/
probes and TOV genome sequence.RESEARCH
similar sequences) to detect any sequence homology. How-
ever, results varied widely in terms of percentage of iden-
tity to their closest BTV sequence and to BTV serotype 
showing the highest similarity (Table 2). No BTV strain 
was distinctly more closely related to TOV than all other 
known sequences, although for several genome segments 
BTV serotype 4 isolates were found to be the closest rela-
tives to TOV. When identity levels between analyzed TOV 
genome segments to their genetically closest BTV strain 
were compared with respective values of the 2 most dis-
tantly related BTV serotypes, TOV sequences were in some 
cases (segments 5, 8, and 10) clearly more different than 
the BTV sequences among themselves. However, for the 
remaining segments, TOV sequences were less different 
from their closest BTV sequence than the 2 most distantly 
related BTV serotypes (segments 2, 6, 7, and 9).
Results of phylogenetic analysis using ClustalW align-
ment (16) and neighbor-joining tree construction conﬁ  rmed 
the results of BLAST analyses by locating some TOV ge-
nome segments within the BTV serogroup (segments 2, 
6, 7, and 9). In contrast, for segments 5, 8, and 10, TOV 
sequences were outside the BTV subtree (Figures 2, 3). 
Furthermore, the S2 gene could not be assigned to any of 
the 9 proposed nucleotypes (17) (data not shown). Despite 
the different placement of the 7 TOV genome segments, 
they were all more closely related to BTV than to any of 
the other known orbivirus species, in particular to EHDV, 
which is the closest relative to BTV (Figures 2, 3).
Discussion
In the context of trade investigations implemented in 
Switzerland shortly after the ﬁ  rst BTV-8 outbreak was de-
tected (11), BTV-speciﬁ  c RNA was detected in clinically 
healthy goats in St. Gallen Canton in northeastern Switzer-
land by segment 10–speciﬁ  c rRT-PCR. However, none of 
the additional rRT-PCR protocols for other BTV genome 
segments, which were performed for conﬁ  rmatory  pur-
poses, yielded positive results. Furthermore, the short (58-
nt) segment 10–speciﬁ  c sequence ampliﬁ  ed by the initial 
rRT-PCR was similar but not identical to any known BTV. 
Therefore, to characterize TOV as a potentially novel BTV, 
we performed a detailed genome analysis by cloning and 
sequencing the entire coding region of most viral genome 
segments.
cDNA of smaller genome segments that encode the 
structural proteins VP5 (segment 6), VP6 (segment 9), VP7 
(segment 7), and nonstructural (NS) proteins NS1 (segment 
5), NS2 (segment 8), and NS3/NS3A (segment 10) could 
be ampliﬁ  ed and sequenced without the need for internal, 
TOV-speciﬁ  c primers. The 2.9-kb region spanning segment 
2 was also included; however, a primer-walking approach 
had to be used for design of TOV-speciﬁ  c sequencing prim-
ers (data not shown). VP2, which is encoded by segment 2, 
is exposed at the virion surface, together with VP5 (3), and 
carries the epitopes inducing serotype-speciﬁ  c neutralizing 
antibodies (18). Thus, segment 2 was expected to contain 
the genetic information enabling assignment of TOV to 1 
of the 24 BTV serotypes.
Although initial attempts to isolate TOV in several 
mammalian cell lines failed, there is preliminary evidence 
that the virus replicates in the highly BTV-susceptible KC 
insect cell line derived from Culicoides spp. (19). How-
ever, to avoid introduction of mutations in the viral genome 
caused by cell culture adaptation, we used blood as the 
source for cloning and nucleotide sequencing of the TOV 
genome.
For accurate identiﬁ  cation of a consensus sequence for 
each cloned TOV genome segment, 5 clones were analyzed 
for each segment. When sequences of individual clones 
were compared, mismatches were found in <1% of the 
nucleotide positions (data not shown), and always in only 
1 of the 5 clones. If one takes into account the error rate of 
the reverse transcriptase and Taq DNA polymerase used to 
transform the viral RNA into PCR-ampliﬁ  ed cDNA, this 
ﬁ  nding supports reported genetic stability of the double-
stranded RNA genome of orbiviruses (20).
BLAST analysis of the ORF sequence of the 7 TOV 
genome segments studied suggested that TOV most likely 
belongs to the BTV serogroup because although the de-
gree of nucleotide sequence identity between TOV and 
the closest BTV relative was low, each of the TOV ge-
nome segments was closely related to BTV and not to an-
other orbivirus. The BLAST results were conﬁ  rmed by 
individual phylogenetic analysis of the 7 TOV genome 
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Table 2. Sequence comparisons of Toggenburg orbivirus genes by BLAST analyses* 
BLAST best hit 
RNA segment  Serotype  Isolate Accession no.  No. identities/total  Identity level, %  Query coverage, %
2 4 Turkey 1999 DQ825670  1,855/2,919 63 100
5 16 TUR2000/10 AM773696 1,242/1,662 75 100
6 4 ARG2002/01 AJ586682 1,163/1,585 73 100
7 23 Dehradoon AJ277802 832/1,050 79 100
8 4 Corsica AY857499 778/1,072 72 100
9 10 10O90H BVU55782 742/1,005 73 100
10 8 8438/vaccine AF512919 550/694 79 100
*Only coding regions of Toggenburg orbivirus genes (including stop codons) were used (http://blast.ncbi.nlm.nih.gov/blast.cgi).Genetic Characterization of Toggenburg Orbivirus
segments. Depending on the segment, TOV was placed 
in a different neighborhood among BTV and EHDV (Fig-
ures 2, 3). Although segments 2, 6, 7, and 9 encoding viral 
structural proteins were placed within the BTV subtree in 
the dendrograms, albeit being distinct from all 24 BTV 
serotypes, the remaining segments 5, 8, and 10 coding for 
NS proteins were located outside the branching area of 
the BTV subtree toward the EHDV subtree. These ﬁ  nd-
ings suggest that TOV might have diverged from BTV 
and evolved independently or could represent a reas-
sortant between BTV and an unknown orbivirus closely 
related to EHDV. This assumption is supported by results 
of BLAST analysis that showed a greater evolutionary 
distance between TOV and BTV than among the various 
BTV serotypes (data not shown), which is evident in the 
case of the segment 10 encoding NS3/NS3A. It will be 
useful to determine whether TOV genome segments 1, 
3, and 4, which encode viral structural proteins, are also 
more closely related to BTV than the NS genes.
Deﬁ  nitive characterization of TOV as a new BTV se-
rotype will require a comprehensive serologic typing with 
BTV serotype–speciﬁ  c antisera and TOV-speciﬁ  c antisera. 
It is likely that TOV represents a new BTV serotype be-
cause agreement of segment 2–based genotypic and serol-
ogy-based phenotypic serotype differentiation, involving a 
large collection of BTV strains representing all 24 known 
serotypes, has been reported (17).
We propose that TOV more likely represents an un-
known 25th serotype of BTV rather than a new orbivirus 
species, on the basis of grouping of structural protein genes 
within BTV and because sera from goats from which the 
virus was isolated showed reactivity in several BTV-spe-
ciﬁ  c antibody ELISAs. These tests did not show reactivity 
with antibodies against EHDV, which represents the closest 
relative to BTV among the orbiviruses (data not shown).
TOV did not cause bluetongue-speciﬁ  c clinical signs 
in experimentally infected goats (V. Chaignat et al., unpub. 
data). In addition, virus load was low. These ﬁ  ndings are 
consistent with the fact that goats generally show no clini-
cal disease after BTV infection but can serve as reservoir 
hosts (1). However, TOV was only sporadically detected 
by rRT-PCR in inoculated sheep, and these animals did not 
show any pronounced clinical signs of bluetongue. If TOV 
also shows an apathogenic phenotype in other ruminants, 
this ﬁ  nding would further support the possibility that TOV 
may have evolved differently than classic BTV strains. 
Identiﬁ  cation of insect vector(s) for TOV would be useful 
because these vector(s) might inﬂ  uence transmission and 
phenotypic properties of TOV.
An apathogenic BTV termed the KM strain has been 
reported in goats from Taiwan (21). This virus was charac-
terized as a typical BTV and was added to BTV reference 
sequences for the present phylogenetic analysis (Figures 2, 
3). On the basis of its high segment 2 sequence similar-
ity with BTV-2 (Figure 2), it is likely that KM belongs to 
this BTV serotype. Comparison of TOV with KM shows 
that TOV is less related to classic BTV than KM, which 
rules out TOV and the KM strain having a common ances-
tor, although the 2 viruses share a high sequence homology 
in their segment 9 ORF (Figure 3). Therefore, TOV might 
represent a reassortant BTV that acquired its segment 9 
from a BTV closely related to KM.
To determine the genetic relationship of TOV with the 
BTV-8 strain currently circulating in northern Europe, the 
segment 10 coding region of the Swiss BTV-8 isolates from 
2 of the late 2007 outbreaks was sequenced and submitted 
to GenBank (accession nos. EU450660 and EU450661). 
This BTV-8 was different from a BTV-8 reference strain 
obtained from the Ofﬁ  ce International des Epizooties Refer-
ence Laboratory for bluetongue (Institute of Animal Health, 
Pirbright, UK) (accession no. EU450663). Although TOV 
was initially detected in Switzerland at the same time as the 
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Figure 2. Phylogenetic analysis of Toggenburg orbivirus (TOV) 
(shaded region) genome segment 2 by ClustalW alignment (16) 
and subsequent neighbor-joining tree construction by MEGA 
version 4 software (15). GenBank accession numbers are indicated 
for all orbivirus sequences used to construct dendrogram. BTV, 
bluetongue virus; EHDV, epizootic hemorrhagic disease virus; 
AHSV, African horse sickness virus. Scale bar indicates number of 
nucleotide substitutions per site. RESEARCH
ﬁ  rst BTV-8 infections, these 2 BTV strains are genetically 
diverse, as shown in the dendrogram of segment 10 (Figure 
3). None of the 7 genome segments analyzed or any of the 3 
remaining genome segments (1, 3, and 4) (data not shown), 
showed sequence homologies >79% with any other BTV, 
and none of the BLAST analyses showed a maximal se-
quence identity level with the corresponding genome seg-
ment of the BTV-8 currently circulating in Europe (22). 
These ﬁ  ndings indicate that TOV is not a reassortant be-
tween BTV-8 and another BTV.
Distinct sequence differences on RNA segments 1 and 
5 may also explain why TOV was not detectable by rRT-
PCR protocols designed to detect a wide range of BTV se-
rotypes (Figure 1). Only the segment 10–speciﬁ  c rRT-PCR 
showed a positive result, whereas all segment 5– and seg-
ment 1–speciﬁ  c assays did not detect TOV. These ﬁ  ndings 
demonstrate the importance of selecting an appropriate 
rRT-PCR protocol for detection of TOV and other unusual 
BTV-like viruses. The fact that most diagnostic laborato-
ries use segment 1– or segment 5–speciﬁ  c rRT-PCRs for 
routine detection of BTV might also explain why TOV has 
never been detected in other regions.
TOV and other BTV-25 strains, as potential apatho-
genic viruses, will have major implications in control of 
bluetongue. A similar situation is found in the United States, 
where several BTV serotypes circulate without causing any 
clinical signs in domestic ruminants; nevertheless, national 
and international animal trade is heavily affected (23).
Additional animal experiments in various ruminant 
species and adaptation of TOV to cell culture for extended 
phenotypic characterization (e.g., replication kinetics) are 
currently under way. TOV-speciﬁ  c rRT-PCR protocols will 
be developed to determine TOV prevalence and to clarify 
its role as an animal pathogen. Furthermore, TOV-speciﬁ  c 
serologic tools that use immunologically dominant epitopes 
of VP2 and VP5 as recombinant ELISA antigens for de-
tection of antibodies to TOV should be developed. These 
tools would facilitate epidemiologic studies to determine 
actual and retrospective seroprevalences of TOV in goats 
and other domestic and wild ruminants in Switzerland and 
throughout the world, in particular in countries that have 
long claimed to be free of BTV infections. Furthermore, 
TOV-speciﬁ  c diagnostic tools will enable identiﬁ  cation of 
natural reservoir(s) and address how and by which insect 
vectors this orbivirus is transmitted.
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Figure 3. Phylogenetic analysis of Toggenburg orbivirus (TOV) (shaded regions) genome segments by ClustalW alignment (16) and 
subsequent neighbor-joining tree construction by MEGA version 4 software (15). GenBank accession numbers are indicated for all 
orbivirus sequences used to construct dendrograms. A) Segment 5; B) segment 6; C) segment 7; D) segment 8; E) segment 9; F) segment 
10. BTV, bluetongue virus; EHDV, epizootic hemorrhagic disease virus. Segments show only relevant parts of dendrograms. **Segment 10 
sequence of BTV-8 currently circulating in northern Europe. Scale bars indicate number of nucleotide substitutions per site.Genetic Characterization of Toggenburg Orbivirus
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